MYM Announces 2019 Planting is Complete at the CBD-Rich Hemp Nevada Project

"I'm happy to report that the CBD-rich hemp seedlings at the Nevada project have now been planted. The planting went as planned and our team of experts will continue to monitor the progress through the harvest and processing stages," said Howard Steinberg, CEO of MYM. "The Nevada project is a key component in our strategy to create a massive CBD-rich hemp footprint around the globe. Nevada serves as a low-risk entry into the US market that is expected to reach $23 billion by 2023." "I'm happy...
VANCOUVER, British Columbia, (informazione.it - comunicati stampa - agricoltura)

"I'm happy to report that the CBD-rich hemp seedlings at the Nevada project have now been planted. The planting went as planned and our team of experts will continue to monitor the progress through the harvest and processing stages," said Howard Steinberg, CEO of MYM. "The Nevada project is a key component in our strategy to create a massive CBD-rich hemp footprint around the globe. Nevada serves as a low-risk entry into the US market that is expected to reach $23 billion by 2023."

Based on previous crops grown on the property, MYM's 50% entitlement of the estimated production is 60,000 lbs of biomass to be converted into 2,694 lbs of CBD isolate generating estimated revenue of $7.1 million for MYM by Q1 2020.

About MYM Nutraceuticals Inc.

MYM Nutraceuticals Inc. is an innovative company focused on the global growth of Cannabis and CBD-rich hemp. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE:MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

ON BEHALF OF THE BOARD

Howard Steinberg, CEO
MYM Nutraceuticals Inc.
www.mym.ca 

Keep up to date with MYM on our social media channels:
Twitter: @mymnutra
Facebook: @mymnutra
Instagram: @mymnutra

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements may include, without limitation, statements relating to the US market expecting to reach $23 billion by 2023, the estimated production of 60,000 lbs of biomass, whether the biomass will be converted into 2,694 lbs of CBD isolate and the expected revenue of $7.1 million by Q1 2020.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

Investor Relations
Billy Casselman
+1-778-522-2261
[email protected]

 

 

 

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Slide ShowSlide Show
Non disponibili